Tirzepatide Research & Studies
Part of the full Tirzepatide guide - a unimolecular dual gip and glp-1 receptor agonist reference compound, identity-verified with a COA on every vial.
In brief
The literature attached to this entry is narrow and explicit: a single primary citation, Coskun et al. 2018 in Molecular Metabolism (DOI 10.1016/j.molmet.2018.09.009, PMID 30473097), supplemented by reference-grade physicochemical and potency data attributed to Selleck Chemicals. The three named research areas frame what bench investigators interrogate with this molecule, and each maps cleanly onto data points the entry actually provides. The sections below summarize those investigational threads attributed only to the provided sources, with no addition of outside studies, numbers, or claims.
The detail
A closer look
01
Dual GIPR / GLP-1R cAMP-signaling potency assays
The first listed research area is dual GIPR / GLP-1R cAMP-signaling potency work, and it is directly supported by the entry's potency data: GIPR EC50 approximately 0.042 nM and GLP-1R EC50 approximately 0.086 nM, sourced to Coskun et al. 2018 and Selleck. This is the foundational characterization - establishing that a single unimolecular agonist activates both class-B receptors' Gs/adenylyl-cyclase/cAMP pathways at sub-nanomolar potency. Investigators use recombinant-cell cAMP-accumulation assays to quantify these EC50 values and to position tirzepatide as the reference dual-incretin agonist against which other engineered incretin analogs are benchmarked. The two-fold potency separation between the receptors is itself a research observable that this assay format resolves.
02
Incretin-receptor structure-activity and DPP-IV-resistance studies
The second research area covers structure-activity relationships and DPP-IV resistance. The entry attributes the molecule's design to a 39-residue GIP-based backbone with Aib substitutions at positions 2 and 13, framing those substitutions as the engineered source of resistance to dipeptidyl-peptidase-IV cleavage. Structure-activity work in this thread asks how specific backbone modifications - the GIP-derived scaffold and the non-natural Aib residues - simultaneously preserve agonism at two receptors while defeating the protease that degrades native incretins. The Coskun et al. 2018 discovery paper is the cited anchor for the sequence and design rationale, with the full sequence noted as 'per Coskun et al. 2018.'
03
Albumin-binding pharmacokinetic-extension research
The third research area, albumin-binding pharmacokinetic extension, is supported by the entry's description of a C20 fatty-diacid side chain that drives reversible albumin binding to extend plasma residence. Research in this thread studies how the acyl moiety's reversible association with serum albumin lengthens the molecule's effective lifetime in plasma-containing systems, a lipidation-based half-life-extension strategy. As a bench observable this is investigated through binding behavior and through the way albumin-containing media shift free-peptide availability, linking the structural acyl feature to functional persistence. All claims here remain within the provided data; the entry makes no human pharmacokinetic, dosing, or therapeutic statement.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. Tirzepatide is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.